SOURCE: Patheon

Patheon

June 15, 2015 09:30 ET

Patheon Announces Biologics Deal With Inhibrx

DURHAM, NC--(Marketwired - June 15, 2015) - Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, has entered into a development contract with Inhibrx, abiologic immunotherapeutic company focused on high, unmet medical needs in oncology, infectious disease and inflammatory conditions.

As part of the agreement, Patheon will develop production processes at its Princeton, N.J., facility and will manufacture products at its Brisbane, Australia, location in support of a pipeline of future programs with Inhibrx. The initial development work will focus on establishing platform processes for Inhibrx's cell lines.

"Early stage biotech companies are the pipeline for our industry and we are excited to work with Inhibrx on their development projects, supporting their strategy through our fast-tracked timelines, robust platforms and technology transfer methodologies," said Manja Bouman, president, Patheon biologics. "By working with our Brisbane facility, Inhibrx is eligible for a cash return under the Australian R&D Tax Incentive, a program in which Patheon's customers may receive attractive incentives, helping to ensure much-needed biopharmaceutical solutions are delivered to the healthcare sector."

"Patheon Biologics has the track record, customer service and scale to support our extensive pipeline of biologic therapeutics. We look forward to working together to rapidly bring innovative therapeutics to patients in need," said Mark Lappe, CEO of Inhibrx.

The announcement was made during a reception hosted by Patheon and opened by the Premier of Queensland, Australia, Annastacia Palaszczuk, on June 14, ahead of the BIO International Conference in Philadelphia.

"The developments send a clear message that Queensland is a great place to invest. We have excellent infrastructure, talented scientists, the rigorous research and the drive to produce outcomes through partnerships," said Ms. Palaszczuk. "You also have a government in Queensland willing to work with business and the research community to grow a strong life sciences industry in the state, to create jobs for Queenslanders and diversify the economy."

Patheon's state of the art Brisbane facility plays a key role in the company's integrated biologics business and global footprint, focused on clinical and commercial drug substance production for biotech companies. Patheon also has biologics sites in St. Louis, Mo., Princeton, N.J., and Groningen, the Netherlands.

Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.

Contact Information